SCHEMBL13507849

SCHEMBL13507849

Cc1cccc(-c2ccc3c(c2)N(C)c2cccc4c2c-3cc2c4c3ccc(-c4cccc(C)c4)cc3n2C)c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ SIRT2 Q8IXJ6 2/20 0.32
▸ RXRA P19793 1/20 0.32
▸ RXRB P28702 1/20 0.32
▸ MAPK14 Q16539 2/20 0.31
▸ RXFP1 Q9HBX9 1/20 0.31
▸ PGR P06401 1/20 0.31
▸ MAOB P27338 2/20 0.31
▸ MAOA P21397 1/20 0.31
▸ PARP10 Q53GL7 1/20 0.30
▸ PARP11 Q9NR21 1/20 0.30
▸ ICMT O60725 1/20 0.30
▸ SIRT1 Q96EB6 1/20 0.30
▸ PDK2 Q15119 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13507370 0.93 L3MBTL1 (0.33) L3MBTL1NPC1RAB9ARXRARXRB
SCHEMBL13507361 0.92 RXRA (0.34) L3MBTL1NPC1RAB9ARXRARXRB
SCHEMBL13507350 0.91 RXRA (0.40) L3MBTL1NPC1RAB9AALDH1A1KDM4E
SCHEMBL13507096 0.85 RXRA (0.37) L3MBTL1NPC1RAB9ARXRARXRB
SCHEMBL13507870 0.85 RXRA (0.40) L3MBTL1NPC1RAB9AALDH1A1KDM4E
SCHEMBL13507356 0.85 AKT1 (0.38) L3MBTL1NPC1RAB9ARXRARXRB
SCHEMBL13507271 0.85 CHEK1 (0.34) L3MBTL1NPC1RAB9ARXRARXRB
SCHEMBL13507299 0.84 CYP11B2 (0.38) MAOA
SCHEMBL13507273 0.84 AKT1 (0.38) L3MBTL1NPC1RAB9ARXRARXRB
SCHEMBL13507199 0.84 RXRA (0.33) L3MBTL1NPC1RAB9AALDH1A1RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100032658-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed
US-20100032658-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100032658-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same OCIAD1, OCIAD2, ORMDL3 L3MBTL1 609/4885NPC1 2317/4885RAB9A 3357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback